Francais
info@saveyourskin.ca

asco

ASCO 2023 Data Report

Earlier this summer, Save Your Skin was fortunate enough to attend the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, in order to hear the latest data from melanoma clinical trials. We are pleased to present the highlights from these exciting studies in our annual ASCO report, which this year includes data from trials relating to melanoma, non-melanoma skin cancers (NMSC), and uveal (ocular) melanoma. Please keep in mind that ASCO is an international association, and therefore studies outlined in this report are not exclusive to Canada.

This report includes:

  • Trial updates related to melanoma, non-melanoma skin cancers (NMSC), and uveal (ocular) melanoma
  • A glossary of abbreviations used in the report
  • A selection of melanoma-related news articles from the summer for supplemental reading

You can read the report here or by clicking on the cover image below. Thank you for reading!

Read more

ASCO 2021 Conference Report by SYSF

The 2021 American Society of Clinical Oncology Annual Meeting took place from June 4-8, 2021. Given the COVID-19 pandemic, the convention was conducted entirely online. This event brings together over thirty thousand oncologists, pharmaceutical representatives, and patient advocates from across the world and across cancer types for five days of networking, learning, and presenting new research. Every year, Save Your Skin Foundation puts together a report of the panels regarding innovative treatments in the melanoma sphere. In this report are detailed recollections of these panels, categorized by topic. All information offered in this report is the intellectual property of the presenter and their team, as cited by the report.

Click here to read the report!

 

Every year, melanoma and uveal melanoma become more widely covered by clinical trials. While the continued innovation of treatment for these cancers is exciting, it means that we were unable to include every presentation and abstract related to melanoma, uveal melanoma, and non-melanoma skin cancers. Therefore, abstracts and presentations that provide updates on safety profiles of past studies and abstracts that do not produce promising clinical results have been excluded. We have also excluded abstracts which, at the time of the meeting, did not have confirmed data.

The informational resources cited in this report are a combination of the transcripts and slides from the ASCO meeting library. All images are courtesy of the author of the respective talk. Any queries may be directed to natalie@saveyourskin.ca

If you are interested in more information from the ASCO 2021 annual meeting, Save Your Skin Foundations is pleased to offer a Post-ASCO 2021 Update with Dr Omid Hamid video concentrated on melanoma, non-melanoma skin cancers, and ocular melanoma. Click HERE to view the recording on youTube

 

Read more

SYSF Webinar: Post-ASCO 2021 Update

Post-ASCO 2021 Update with Dr. Hamid: Melanoma, Non-Melanoma Skin Cancers, and Ocular Melanoma

Presented by Dr. Omid Hamid, The Angeles Clinic and Research Institute, Los Angeles, California, this webinar  reviews late breaking news, key takeaways, clinical data and other updates presented at the American Society of Clinical Oncology (ASCO) Annual Meeting that took place in a virtual format in June 2021.

Dr. Hamid shares his key insights into what the landscape of melanoma, non-melanoma skin cancers, and ocular melanoma treatment looks like for the near future.  As Director of the Melanoma Center at The Angeles Clinic and Research Institute, Dr. Omid Hamid works to ensure that patients receive access to the most up-to-date therapeutics, based on molecular pathways of melanoma progression. Dr. Hamid is recognized as one of the preeminent Immuno-Oncologists and melanoma specialists in the world.

Click HERE to view the Presentation Recording on our youTube channel

Read more

ASCO 2020 Event Report

In 2020, the American Society of Clinical Oncology meeting was held online due to the COVID-19 pandemic. The meeting took place from May 29th-31st, with the last two days being devoted to online presentations.

This report will be dedicated to the presentations that representatives from Save Your Skin Foundation remotely attended, with a focus on melanoma, innovative treatments, and survivorship. The information in this report is sourced directly, occasionally verbatim, from ASCO presentations and abstracts. If you require more information on an abstract, the clinical trial numbers (where available) are included for your reference.

Please CLICK HERE to read or download the report.

 

Feedback or questions?  Contact us – info@saveyourskin.ca

Read more

ASCO 2019 Event Report

The 2019 American Society of Clinical Oncology Annual Meeting took place from May 31-June 4, 2019 in Chicago, Illinois. This event brings together over thirty thousand oncologists, pharmaceutical representatives, and patient advocates from across the world and across cancer types for five days of networking, learning, and presenting new research.

Every year, Save Your Skin Foundation puts together a report of the panels regarding updates on the innovative treatment of melanoma, non-melanoma skin cancer, and ocular melanoma. Included in the report are detailed recollections of these panels, in chronological order.

Please CLICK HERE to download and read the report.

 

Feedback or questions?  Contact us – info@saveyourskin.ca

Read more

Best of ASCO: Montréal!

Updated 3-August-2018: Click HERE to find our full report from ASCO 2018!

 

***

While we’re finishing up our report on the ASCO Annual Meeting 2018 in Chicago, we’d like to share with you some resources about trials that were discussed at an ASCO satellite meeting: Best of ASCO 2018 Montréal, which took place in Montréal, QC on June 19th, 2018. From 7:50-8:20 pm, Dr. Wilson Miller (McGill) gave a talk entitled “Best of Melanoma,” which highlighted some of the notable melanoma studies discussed at the ASCO annual meeting.

For those interested in more ASCO recaps, Oncology Education has posted video resources, including Dr. Jeffrey Weber (NYU) discussing Checkmate 238, Dr. Max Madu (Netherlands Cancer Institute) on the 8th AJCC melanoma staging system, and a roundtable discussion of ASCO highlights with Dr. Marcus Butler (Princess Margaret Cancer Centre), Dr. John Walker (Alberta Cancer Centre), and Dr. Jason Luke (University of Chicago). These videos are available here, though you will need to register for the Oncology Education website to view them.

Below is a list of some of the trials Dr. Miller presented, with links to the ASCO abstracts for further reading:

 

Abstract number 9501: “Final analysis of DeCOG-SLT trial: Survival outcomes of complete lymph node dissection in melanoma patients with positive sentinel node.”

Presented at ASCO Annual Meeting, Chicago, in the Melanoma/Skin Cancers Oral Abstract Session (Monday, June 4, 8:00-11:00 AM).

Authors: Ulrike M. Leiter et al.

Retrieved from: http://abstracts.asco.org/214/AbstView_214_216115.html

The DeCOG-SLT trial assessed whether complete lymph node dissection can result in increased survival compared with observation in patients with positive sentinel node biopsy in a randomized phase III trial. The update presented at ASCO 2018 comes three years after the inclusion of the last patient. After the median 72-month follow-up time, there seemed to be no survival benefit in patients with positive sentinel node biopsy with complete lymph node dissection, compared to observation. More information about the methods and results of the study can be found at the link above.

 

Abstract number 9503: “4-year Survival and Outcomes After Cessation of Pembrolizumab (pembro) after 2-years in Patients (pts) with Ipilimumab (ipi)-naive Advanced Melanoma in KEYNOTE-006 [NCT01866319]”

Presented at ASCO Annual Meeting, Chicago, in the Melanoma/Skin Cancers Oral Abstract Session (Monday, June 4, 8:00-11:00 AM).

Authors: Georgina V. Long et al.

Retrieved from: http://abstracts.asco.org/214/AbstView_214_222303.html.

The KEYNOTE-006, or NTO1866319, sought to establish the efficacy of pembrolizumab over ipilimumab in advanced melanoma. The data includes four year outcomes, long term data for patients who have completed two years of pembro, and data for second course. The results suggest that pembrolizumab can provide durable anti-tumour activity in treatment-naive or previously treated patients. 86% of the patients who had completed two years of pembro were progression free at 20 months. The data suggests that pembro is safe, and can be used as a second-course treatment to provide additional anti-tumour activity. For more information, see the link above.

 

Abstract number 9594: “Assessing the Value of Nivolumab (NIVO) versus Placebo (PBO) and Ipilimumab (IPI) as Adjuvant Therapy for Resected Melanoma [EORTC 18071]

Presented at ASCO Annual Meeting, Chicago, in the Melanoma/Skin Cancers Oral Abstract Session (Monday, June 4, 8:00-11:00 AM).

Authors: Morganna Louise Freeman et al.

Retrieved from: http://abstracts.asco.org/214/AbstView_214_220221.html.

This study assessed the cost of cancer therapies in the context of clinical benefits. Data from CheckMate 238 and EORTC 18071 (nivolumab) was compared to placebo and ipilimumab in the adjuvant setting for patients with resected melanoma was used to consider the cost for each recurrence-free life month (RFLM) and associated medical costs. They found that nivo has a lower medical cost per RFLM than both placebo and ipi in patients with resected IIIB and IIIC cutaneous melanoma, and has superior drug costs per RFLM relative to placebo and ipi over eighteen months. Data suggests that follow-up will continue to determine the cost-effectiveness of adjuvant NIVO. For methods, results, and outcome measures, see the link above.

 

Abstract number 9502: “Adjuvant Therapy with Nivolumab (NIVO) versus Ipilimumab (IPI) After Complete Resection of Stage III/IV Melanoma: Updated Results from a Phase III Trial (CheckMate 238)”

Presented at ASCO Annual Meeting, Chicago, in the Melanoma/Skin Cancers Oral Abstract Session (Monday, June 4, 8:00-11:00 AM).

Authors: Jeffrey S. Weber et al.

Retrieved from: http://abstracts.asco.org/214/AbstView_214_214567.html.

With a minimum follow-up of 18 months, the initial report data from the CheckMate 238 trial demonstrated that nivolumab had longer recurrence-free survival over ipilimumab in patients with resected stage III or IV melanoma. At ASCO, phase III data with an additional six months of follow-up was reported. With this extended follow-up, nivo continued to demonstrated a sustained benefit versus ipi for patients with resected stage III/IV melanoma at a high risk of recurrence, PD-L1 expression, or BRAF mutation. More information can be retrieved at the link above.

 

Abstract number 9514: “Phase II Trial of Pembrolizumab (pembro) plus 1 mg/kg Ipilimumab (ipi) Immediately Following Progression on Anti-PD-1 Ab in Melanoma (mel)”

Presented at the ASCO Annual Meeting 2018, Chicago, in the Melanoma/Skin Cancer Poster Session (Monday, June 4, 1:15-4:45 PM).

Authors: Daniel Olsen et al.

Retrieved from: http://abstracts.asco.org/214/AbstView_214_215997.html.

This study sought to examine the role of the immunotherapy anti-PD-1 + CTLA-4 combination after the first line anti-PD-1. They are reporting the first potential data examining pembrolizumab + low dose ipilimumab following progression on anti-PD-1. The results suggest that low dose ipi + pembro is tolerable and has anti-tumour activity in melanoma patients who have progressed on an anti-PD-1 immediately prior. For more information on this abstract and ongoing trial, see the link above.

 

Abstract number 9542: “BRAF/MEK Inhibition in Melanoma Patients with Rare BRAF Mutations”

Presented at the ASCO Annual Meeting 2018, Chicago, in the Melanoma/Skin Cancer Poster Session (Monday, June 4, 1:15-4:45 PM).

Authors: Jessica Cecile Hassel et al.

Retrieved from: http://abstracts.asco.org/214/AbstView_214_226845.html.

This study uncovered efficacy data for BRAF/MEK inhibition, which is standard care for patients with BRAF V600E/K mutated melanoma. The results suggest that patients with tate BRAF mutations often respond to targeted therapy. Less likely to respond to BRAFi monotherapy are patients with non-V600 mutations, but MEKi as monotherapy or combined with BRAFi seems more promising for these patients. For more information, including a data breakdown, see the link above.

 

We hope this information was interesting and helpful– stay tuned to our social media channels for study news, and our upcoming ASCO Annual Meeting 2018 report!

Read more

American Society of Clinical Oncology Annual Meeting 2018!

Once again, Save Your Skin attended the American Society of Clinical Oncology (ASCO) annual meeting, which took place from June 1-5 at McCormick Place in Chicago. The meeting brought together physicians and oncologists, pharmaceuticals, and patient advocates from all cancer types. ASCO, as an organization and at the conference, creates a space for advocacy networking and education, including spaces for advocates to meet, presentations, and a panel track devoted to patient and survivor care. You can read more about ASCO’s interest in patient education here, and visit cancer.net for ASCO’s resources for patient education. These patient and survivor care panels, alongside the melanoma and developmental therapeutics offerings, kept us busy throughout the conference.

While we are working on a more extensive ASCO report, we’d like to share some of the highlights from our social media feed and from the ASCO daily news. Stay tuned for more updates, and more detailed descriptions of the panels we attended.

 

https://www.instagram.com/p/Bjh9PdlnmvL/?taken-by=saveyourskinfdn

 

 

 

 

 

More highlights to be posted over social media and report to come soon! Stay tuned!

 

Read more

February Conference Recap: Canadian Melanoma Conference and ASCO SITC

As February comes to a close, we’d like to look back on the conferences we attended this month: the Canadian Melanoma Conference and the American Society of Clinical Oncology (ASCO) meeting in Orlando, Florida!

Here is a sample of our social media from these conferences!

Canadian Melanoma Conference

 

ASCO Florida

 

 

Read more